Inovio HBV immunotherapy candidate INO-1800 shows encouraging action in early-stage study; shares ahead 5 …Seeking AlphaInovio Pharmaceuticals (NYSEMKT:INO) is up 5% premarket on light volume on the heels of its announcement of positive preliminary r… Continue reading
The Lincolnian OnlineBeyondspring (BYSI) and Editas Medicine (EDIT) Critical ContrastThe Ledger GazetteIt is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology. CRISPR uses a pro… Continue reading
Verdict |
How gene manipulation tech Crispr will transform medicine and agriculture
Verdict Financial problems cause two Deliciously Ella deli closures. Jennifer Doudna, inventor of revolutionary gene editing technique Crispr, expects the technology to transform agriculture and medicine. In an interview with the Financial Times – forming part … Agriculture First for CRISPRGenomeWeb Jennifer Doudna: ‘I still remember my first encounter with DNA’Financial Times |
Immuno-Oncology News |
New Type of CAR T-cells Offers Hope for ‘First Viable’ Treatment of T-cell Blood Cancers, Study Reports
Immuno-Oncology News T-cells, a type of white blood cell, recognize foreign molecules through specific membrane receptors. T-cell receptors can be genetically altered to specifically recognize and kill tumor cells, a therapy called chimeric antigen receptors (CAR) T-cell … |
Genetic Literacy Project |
Viewpoint: GlaxoSmithKline abandonment of rare disease gene–therapy drug program because it’s not a money …
Genetic Literacy Project When GlaxoSmithKline, long a global leader in the effort to pioneer gene replacement therapies, announced it would halt its drug development program for rare diseases, I understood that the decision made practical sense for the company. But as the … |
|
Inovio’s DNA Immunotherapy Demonstrates Immune Response Results Key in Treating Chronic Hepatitis B Infection
GlobeNewswire (press release) PLYMOUTH MEETING, Pa., March 14, 2018 (GLOBE NEWSWIRE) — Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that interim Phase 1 results show its DNA immunotherapy designed to treat hepatitis B virus (HBV) infection was safe, well-tolerated and … Inovio Pharma (INO) Announces Interim Phase 1 Results for DNA Immunotherapy to Treat HBVStreetInsider.com |